<DOC>
	<DOCNO>NCT00321984</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Dexlansoprazole modify release ( MR ) ( 30 mg daily [ QD ] 60 mg QD ) compare placebo relief daytime nighttime heartburn 4 week subject symptomatic , nonerosive gastroesophageal reflux disease ( GERD ) .</brief_summary>
	<brief_title>Safety Efficacy Dexlansoprazole Modified Release Formulation Treat Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , multicenter , placebo-controlled , 3-arm study 4 week treatment period . This study compare efficacy Dexlansoprazole MR ( 30 mg QD 60 mg QD ) placebo administer orally single daily dose morning , breakfast . The study design evaluate symptom relief subject symptomatic nonerosive GERD . Approximately 900 subject enrol approximately 200 United States ( US ) potentially ex-US site . The study consist two period : screening period , last minimum 7 day maximum 21 day , treatment period , last 4 week .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Subjects identify main symptom burn feel mid epigastric area and/or chest area ( ie , heartburn ) . Subject history episode heartburn 6 month longer prior Screening . Subject must history episode heartburn 4 day 7 day prior Day 1 . Endoscopic Barrett 's esophagus and/or definite dysplastic change . History dilatation esophageal stricture . Subjects erosive esophagitis ( EE ) show endoscopy . Evidence uncontrolled systemic disease . Coexisting disease affect esophagus . Current history ZollingerEllison syndrome . Subject abnormal laboratory value . Subjects active gastric duodenal ulcer within 4 week first dose . Subject know acquired immunodeficiency syndrome ( AIDS ) . Known hypersensitivity proton pump inhibitor ( PPI ) , component Dexlansoprazole MR , antacid . Use prescription nonprescription PPIs , histamine ( H2 ) receptor antagonist , sucralfate . Chronic ( &gt; 12 dos per month ) use nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor . Use antacid ( except studysupplied GelusilÂ® ) . Use drug significant anticholinergic effect . Subjects discontinue use misoprostol prokinetics Need continuous anticoagulant therapy . Females pregnant lactating . History gastrointestinal surgery except simple oversew ulcer . History cancer within 3 year prior screen . Subject participate previous Dexlansoprazole study . Subjects , opinion investigator , unable comply requirement study unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Gastroesophageal Reflux Disease ( GERD )</keyword>
	<keyword>Heartburn</keyword>
</DOC>